Overview: NGS Usher Syndrome Sequencing TestIntroduction: The NGS Usher Syndrome Sequencing Test sequences genes to diagnose Usher syndrome, causing hearing and vision loss. Following 2023 AAO guidelines, it uses PCR for high specificity, supporting vision and hearing screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected Usher syndrome.
Other Names: Usher Syndrome Assay, USH2A/MYO7A Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Usher syndrome sequencing began in the 1990s with sensory disorder research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose Usher syndrome, guides treatment, and evaluates patients with hearing and vision loss.
Test Parameters: 1. Usher Syndrome Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of hearing loss, vision loss, or Usher syndrome symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document hearing loss, retinitis pigmentosa, balance issues, or family history of Usher syndrome. Include current medications, especially hearing or vision aids.
Consent: Written consent required, detailing the tests purpose, Usher syndrome implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze Usher syndrome genes (e.g., USH2A, MYO7A). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for Usher syndrome diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm Usher syndrome, guiding cochlear implants, vision aids, or genetic counseling. Negative results may require broader sensory panels.
Specialist Consultation: Consult an ophthalmologist, audiologist, or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Audiometry, ERG, or retinal imaging to confirm Usher syndrome diagnosis.
Test Limitations: Not all Usher syndrome cases are detected; clinical correlation is needed. Sample quality affects sensitivity.
References: AAO Usher Syndrome Guidelines, 2023; American Journal of Human Genetics, Petit C, 2022.
